{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:38:51Z","timestamp":1790959131401,"version":"4.1.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.addr.2022.114582","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:17:40Z","timestamp":1666552660000},"page":"114582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["Novel drug delivery systems for the management of dry eye"],"prefix":"10.1016","volume":"191","author":[{"given":"Noriaki","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114582_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop (2007)","volume":"5","author":"Lemp","year":"2007","journal-title":"Ocular Surf."},{"key":"10.1016\/j.addr.2022.114582_b0010","first-page":"71","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.addr.2022.114582_b0015","first-page":"192","article-title":"Dry eye syndrome","volume":"6","author":"Javadi","year":"2011","journal-title":"J. Ophthalmic Vis. Res."},{"issue":"5","key":"10.1016\/j.addr.2022.114582_b0020","doi-asserted-by":"crossref","first-page":"e0215130","DOI":"10.1371\/journal.pone.0215130","article-title":"\u201cSmart Eye Camera\u201d: An innovative technique to evaluate tear film breakup time in a murine dry eye disease model","volume":"14","author":"Shimizu","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2022.114582_b0025","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.286.17.2114","article-title":"Hormone Replacement Therapy and Dry Eye Syndrome","volume":"286","author":"Schaumberg","year":"2001","journal-title":"JAMM."},{"key":"10.1016\/j.addr.2022.114582_b0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/978-1-4615-0717-8_140","article-title":"Epidemiology of dry eye syndrome","volume":"506","author":"Schaumberg","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2022.114582_b0035","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on Clinical Trials in Dry Eyes","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J."},{"key":"10.1016\/j.addr.2022.114582_b0040","series-title":"Duane\u2019s Foundations of Clinical Ophthalmology, Lippincott Williams & Wilkins","article-title":"The tear film, in Foundation Volume 2: Physiology of the Eye and Visual System","author":"Peters","year":"2006"},{"key":"10.1016\/j.addr.2022.114582_b0045","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.preteyeres.2004.04.003","article-title":"Changes in the tear film and ocular surface from dry eye syndrome","volume":"23","author":"Johnson","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/683153","article-title":"Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies","volume":"2014","author":"Wagh","year":"2014","journal-title":"Journal of Nanotechnology"},{"key":"10.1016\/j.addr.2022.114582_b0055","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/eye.2010.7","article-title":"Tear proteomics in evaporative dry eye disease","volume":"24","author":"Versura","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.addr.2022.114582_b0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1542-0124(12)70096-4","article-title":"Isolation of the Ocular Surface to Treat Dysfunctional Tear Syndrome Associated with Computer Use","volume":"5","author":"Yee","year":"2007","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.addr.2022.114582_b0065","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2012.06.064","article-title":"Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction","volume":"119","author":"Foulks","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archopht.116.7.849","article-title":"Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality","volume":"116","author":"Shine","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0075","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ajo.2005.05.025","article-title":"Correlation Between Dry Eye and Rheumatoid Arthritis Activity","volume":"140","author":"Fujita","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0080","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/978-1-4615-0717-8_140","article-title":"Epidemiology of Dry Eye Syndrome","volume":"506","author":"Schaumberg","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2022.114582_b0085","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0002-9394(14)71688-5","article-title":"Prevalence of Dry Eye Among the Elderly","volume":"124","author":"Schein","year":"1997","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000099263","article-title":"Regulatory T Cells and the Eye","volume":"92","author":"Niederkorn","year":"2007","journal-title":"Chem. Immunol. Allergy"},{"key":"10.1016\/j.addr.2022.114582_b0095","series-title":"Chemical Immunology and AllergyImmune Response and the Eye","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000099268","article-title":"Dry Eye Syndromes","author":"Barabino","year":"2007"},{"key":"10.1016\/j.addr.2022.114582_b0100","first-page":"2283","article-title":"Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease","volume":"42","author":"Solomon","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0105","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9394(03)00203-4","article-title":"Abnormal protein profilesin tears with dry eye syndrome","volume":"136","author":"Ohashi","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/112067210501500602","article-title":"The Triple Classification of Dry Eye for Practical Clinical Use","volume":"15","author":"Murube","year":"2005","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.exer.2003.09.009","article-title":"Impression cytology of the ocular surface: a review","volume":"78","author":"Calonge","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000310101","article-title":"Conjunctival Surface Damage Distribution in Keratoconjunctivitis Sicca. An Impression Cytology Study","volume":"200","author":"Rolando","year":"1990","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.addr.2022.114582_b0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00003226-200009000-00009","article-title":"The Diagnosis and Management of Dry Eye: A Twenty-Five-Year Review","volume":"19","author":"Pflugfelder","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0161-6420(99)90170-7","article-title":"Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms","volume":"106","author":"Afonso","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.exer.2003.09.020","article-title":"Non-invasive methods of assessing the tear film","volume":"78","author":"Yokoi","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1542-0124(12)70083-6","article-title":"Methodologies to Diagnose and Monitor Dry Eye Disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop (2007)","volume":"5","author":"Bron","year":"2007","journal-title":"Ocular Surf."},{"key":"10.1016\/j.addr.2022.114582_b0145","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ajo.2010.10.032","article-title":"Tear Osmolarity in the Diagnosis and Management of Dry Eye Disease","volume":"151","author":"Lemp","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0155","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","article-title":"The International Workshop on Meibomian Gland Dysfunction: Executive Summary","volume":"52","author":"Nichols","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0160","doi-asserted-by":"crossref","unstructured":"G. de Oliveira Fulg\u00eancio, J.B. Saliba, S.L. Fialho, A. da Silva Cunha J\u00fanior, Cyclosporine-loaded delivery system for the treatment of keratoconjunctivitis sicca: a pilot study, Rev. Bras. Oftalmol. 72 (2013) 232\u2013236, https:\/\/doi.org\/10.1590\/S0034-72802013000400005.","DOI":"10.1590\/S0034-72802013000400005"},{"key":"10.1016\/j.addr.2022.114582_b0165","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1167\/iovs.16-19309","article-title":"Reduced Levels of Tear Lacritin Are Associated With Corneal Neuropathy in Patients With the Ocular Component of Sj\u00f6gren's Syndrome","volume":"57","author":"McNamara","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0170","doi-asserted-by":"crossref","unstructured":"A. Lambiase, B.D. Sullivan, T.A. Schmidt, D.A. Sullivan, G.D. Jay, E.R. Truitt 3rd, A. Bruscolini, M. Sacchetti, F. Mantelli, A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 \u03bcg\/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed\u00ae) in Patients with Moderate Dry Eye Disease, Ocular Surf. 15 (2017) 77\u201387, https:\/\/doi.org\/10.1016\/j.jtos.2016.08.004.","DOI":"10.1016\/j.jtos.2016.08.004"},{"key":"10.1016\/j.addr.2022.114582_b0175","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/jop.2020.0014","article-title":"Loteprednol Etabonate for the Treatment of Dry Eye Disease","volume":"36","author":"Beckman","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0180","first-page":"3476","article-title":"Efficacy and Safety of OCS-02 a novel, potent, topical TNF\u03b1 antibody in acute anterior uveitis (AAU): a phase 2 study","volume":"62","author":"Galor","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0185","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0190","doi-asserted-by":"crossref","unstructured":"I. Varela Rey, M. Gonzalez-Barcia, L. Garc\u00eda-Quintanilla, A. Castro-Balado, M. Busto-Iglesias, I. Zarra-Ferro, A. Fern\u00e1ndez-Ferreiro, 4CPS-323 Evaluation of the use, adherence and tolerance of 0.03% tacrolimus eye drops, Eur. J. Hosp. Pharm. 28 (2021) A76, http:\/\/dx.doi.org\/10.1136\/ejhpharm-2021-eahpconf.155.","DOI":"10.1136\/ejhpharm-2021-eahpconf.155"},{"key":"10.1016\/j.addr.2022.114582_b0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/jop.2015.0032","article-title":"Preformulation Studies of a Liposomal Formulation Containing Sirolimus for the Treatment of Dry Eye Disease","volume":"32","author":"Linares-Alba","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0200","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/ICL.0000000000000414","article-title":"Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases","volume":"44","author":"Kovalchin","year":"2018","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.addr.2022.114582_b0205","doi-asserted-by":"crossref","unstructured":"K. Cholkar, B.C. Gilger, A.K. Mitra, Corrigendum to \u201cTopical delivery of aqueous micellar Resolvin E1 analog (RX-10045)\u201d [Int. J. Pharm. 498 (2016) 326-334], Int. J. Pharm. 509 (2016) 528, https:\/\/doi.org\/10.1016\/j.ijpharm.2016.04.012.","DOI":"10.1016\/j.ijpharm.2016.04.012"},{"key":"10.1016\/j.addr.2022.114582_b0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/02713680601147690","article-title":"Albumin rescues ocular epithelial cells from cell death in dry eye","volume":"32","author":"Higuchi","year":"2007","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0215","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s12325-021-01680-3","article-title":"Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease","volume":"38","author":"Schmidl","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0220","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1167\/iovs.18-23860","article-title":"Effects of Topical Mucolytic Agents on the Tears and Ocular Surface: A Plausible Animal Model of Mucin-Deficient Dry Eye","volume":"59","author":"Li","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0225","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1038\/s41598-018-28861-5","article-title":"RGN-259 (thymosin \u03b24) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.addr.2022.114582_b0230","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10561-021-09962-4","article-title":"Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies","volume":"23","author":"P\u00e9rez","year":"2022","journal-title":"Cell Tissue Bank"},{"key":"10.1016\/j.addr.2022.114582_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107905","article-title":"Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype","volume":"191","author":"Lu","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0240","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","article-title":"Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye","volume":"7","author":"Meerovitch","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0245","first-page":"384","article-title":"Ecabet Sodium Promotes MUC5AC Secretion in Rabbit Tears","volume":"48","author":"Mito","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0250","first-page":"1913","article-title":"Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro","volume":"16","author":"He","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2022.114582_b0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/10807680260218515","article-title":"Corneal Protection by the Ocular Mucin Secretagogue 15(S)-HETE in a Rabbit Model of Desiccation-induced Corneal Defect","volume":"18","author":"Gamache","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0260","doi-asserted-by":"crossref","first-page":"9281519","DOI":"10.1155\/2017\/9281519","article-title":"Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome","volume":"2017","author":"Zernii","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.addr.2022.114582_b0265","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0270","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/archopht.1992.01080160106043","article-title":"Preservative-Free Artificial Tear Preparations: Assessment of Corneal Epithelial Toxic Effects","volume":"110","author":"Berdy","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/jop.1994.10.83","article-title":"Mucoadhesive Ophthalmic Vehicles: Evaluation of Polymeric Low-Viscosity Formulations","volume":"10","author":"Saettone","year":"1994","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/j.addr.2022.114582_b0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijpharm.2008.07.028","article-title":"Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity","volume":"364","author":"Gokce","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0285","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jconrel.2011.12.016","article-title":"Cyclosporin pro-dispersion liposphere formulation","volume":"160","author":"Avramoff","year":"2012","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114582_b0290","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","article-title":"Evaluation of Topical Cyclosporine for the Treatment of Dry Eye Disease","volume":"126","author":"Perry","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0295","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of Topical Cyclosporine Treatment of Patients with Dry Eye Syndrome: Effect on Conjunctival Lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.addr.2022.114582_b0305","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0976-500X.195920","article-title":"Lifitegrast: A novel drug for treatment of dry eye disease","volume":"7","author":"Abidi","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.addr.2022.114582_b0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2022.114582_b0315","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/ICO.0000000000002452","article-title":"Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies","volume":"40","author":"Korenfeld","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0320","series-title":"Dry Eye and Ocular Surface Disorders","first-page":"309","article-title":"Therapy of lacrimal keratoconjunctivitis","author":"Pflugfelder","year":"2004"},{"key":"10.1016\/j.addr.2022.114582_b0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00002512-200825020-00003","article-title":"Pharmacological Management of Dry Eye in the Elderly Patient","volume":"25","author":"Foulks","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.addr.2022.114582_b0330","unstructured":"Y. Takaoka-Shichijo, T. Murakami, M. Nakamura, [Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbits], Atarashii Ganka, 28 (2011)1029-1033, Japanese."},{"key":"10.1016\/j.addr.2022.114582_b0335","unstructured":"Y. Takaoka-Shichijo, M. Nakamura, [Stimulatory effect of diquafosol tetrasodium on the expression of membrane-binding mucin genes in cultured human corneal epithelial cells], Atarashii Ganka, 28 (2011) 425\u2013429, Japanese."},{"key":"10.1016\/j.addr.2022.114582_b0340","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","article-title":"Diquafosol Ophthalmic Solution for Dry Eye Treatment","volume":"29","author":"Nakamura","year":"2012","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0345","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"Rebamipide Ophthalmic Suspension Phase 3 Study Group, A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0350","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide Ophthalmic Suspension Phase II Study Group, Rebamipide (OPC-12759) in the Treatment of Dry Eye: A Randomized, Double-Masked, Multicenter, Placebo-Controlled Phase II Study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0355","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.ico.0000208819.24990.0d","article-title":"OPC-12759 Increases Proliferation of Cultured Rat Conjunctival Goblet Cells","volume":"25","author":"R\u00edos","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0360","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide Increases the Amount of Mucin-like Substances on the Conjunctiva and Cornea in the N-Acetylcysteine-Treated In Vivo Model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0365","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3892\/etm.2014.2108","article-title":"Histological observation of goblet cells following topical rebamipide treatment of the human ocular surface: A case report","volume":"9","author":"Kase","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.addr.2022.114582_b0370","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaophthalmol.2014.431","article-title":"Effect of Topical Rebamipide on Human Conjunctival Goblet Cells","volume":"132","author":"Kase","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0375","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","article-title":"Effect of Rebamipide Ophthalmic Suspension on Optical Quality in the Short Break-up Time Type of Dry Eye","volume":"32","author":"Koh","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0380","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1542-0124(12)70214-8","article-title":"Essential Fatty Acids in the Treatment of Dry Eye","volume":"8","author":"Rosenberg","year":"2010","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.addr.2022.114582_b0385","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.sjopt.2014.06.004","article-title":"Essential fatty acids in the treatment of dry eye syndrome: A myth or reality?","volume":"28","author":"Al Mahmood","year":"2014","journal-title":"Saudi J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archophthalmol.2007.61","article-title":"Topical Omega-3 and Omega-6 Fatty Acids for Treatment of Dry Eye","volume":"126","author":"Rashid","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","article-title":"Efficacy of Commercially Available Topical Cyclosporine A 0.05% in the Treatment of Meibomian Gland Dysfunction","volume":"25","author":"Perry","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0400","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1167\/iovs.13-13577","article-title":"Therapeutic Effects of Topical Doxycycline in a Benzalkonium Chloride-Induced Mouse Dry Eye Model","volume":"55","author":"Zhang","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0405","article-title":"Ophthalmic solution with tetracycline for topical treatment of dry eye disease, Advanced Vision Research LLC., Ann","volume":"EP1105139 B1","author":"Gilbard","year":"2004","journal-title":"Arbor"},{"key":"10.1016\/j.addr.2022.114582_b0410","first-page":"1447","article-title":"Managing Sj\u00f6gren\u2019s Syndrome and non-Sj\u00f6gren Syndrome dry eye with anti-inflammatory therapy","volume":"8","author":"Coursey","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0415","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ophtha.2013.07.006","article-title":"Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group, Bromfenac Ophthalmic Solution 007% Dosed Once Daily for Cataract Surgery: Results of 2 Randomized Controlled Trials","volume":"121","author":"Walters","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2022.114582_b0420","first-page":"112","article-title":"Efficacy of Several Therapeutic Agents in a Murine Model of Dry Eye Syndrome","volume":"66","author":"Kilic","year":"2016","journal-title":"Comp. Med."},{"key":"10.1016\/j.addr.2022.114582_b0425","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/ICO.0b013e31824988e5","article-title":"The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes","volume":"31","author":"Liu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0430","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/eye.1989.64","article-title":"The ocular surface in keratoconjunctivitis sicca","volume":"3","author":"Bron","year":"1989","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2022.114582_b0435","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0002-9394(78)90177-0","article-title":"Topical Retinoic Acid in the Treatment of Corneal Xerophthalmia","volume":"86","author":"Sommer","year":"1978","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0440","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0445","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/OPTH.S296510","article-title":"Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra\u00ae) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease","volume":"15","author":"Hovanesian","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jop.2016.0105","article-title":"LFA-1\/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease","volume":"33","author":"Pflugfelder","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program","volume":"22","author":"Chan","year":"2019","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0460","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0002-9394(00)00620-6","article-title":"Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome","volume":"131","author":"Balaram","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0465","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","article-title":"Randomized Controlled Crossover Trial Comparing the Impact of Sham or Intranasal Tear Neurostimulation on Conjunctival Goblet Cell Degranulation","volume":"177","author":"Gumus","year":"2017","journal-title":"Am. J. Ophthalmol"},{"key":"10.1016\/j.addr.2022.114582_b0470","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.2147\/OPTH.S284622","article-title":"Stimulating Tear Production: Spotlight on Neurostimulation","volume":"15","author":"Yu","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0475","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcjo.2017.07.026","article-title":"EyePrintPRO therapeutic scleral contact lens: indications and outcomes","volume":"53","author":"Nguyen","year":"2018","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0480","first-page":"4","article-title":"Advanced drug delivery for dry eye treatment","volume":"104","author":"Kraus","year":"2020","journal-title":"ONdrugDelivery Magazine"},{"key":"10.1016\/j.addr.2022.114582_b0485","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics10010028","article-title":"Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases","volume":"10","author":"Bachu","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2022.114582_b0490","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/nn4046024","article-title":"Sustained Drug Release in Nanomedicine: A Long-Acting Nanocarrier-Based Formulation for Glaucoma","volume":"8","author":"Natarajan","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114582_b0495","first-page":"96","article-title":"Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity, Recent Pat","volume":"2","author":"Boddu","year":"2012","journal-title":"Nanomed."},{"key":"10.1016\/j.addr.2022.114582_b0500","series-title":"Ocular Drug Delivery","first-page":"219","author":"Vadlapudi","year":"2015"},{"key":"10.1016\/j.addr.2022.114582_b0505","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114582_b0510","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.2042-7158.1991.tb03534.x","article-title":"Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles","volume":"43","author":"Losa","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114582_b0515","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1023\/A:1018977130559","article-title":"Design of New Formulations for Topical Ocular Administration: Polymeric Nanocapsules Containing Metipranolol","volume":"10","author":"Losa","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114582_b0520","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/138920007779815977","article-title":"Ocular Disposition, Pharmacokinetics, Efficacy and Safety of Nanoparticle-Formulated Ophthalmic Drugs","volume":"8","author":"Bu","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2022.114582_b0525","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114582_b0530","doi-asserted-by":"crossref","first-page":"028","DOI":"10.29328\/journal.hps.1001005","article-title":"Nano-formulations for Ophthalmic Treatments","volume":"1","author":"John","year":"2017","journal-title":"Arch. Pharm. Pharma. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0535","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","article-title":"Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation","volume":"125","author":"Soiberman","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2022.114582_b0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.7.5.24","article-title":"Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease","volume":"7","author":"Coursey","year":"2018","journal-title":"Transl. Vis. Sci. Techn."},{"key":"10.1016\/j.addr.2022.114582_b0545","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/chem.201504355","article-title":"A Divalent PAMAM-Based Matrix Metalloproteinase\/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome","volume":"22","author":"Richichi","year":"2016","journal-title":"Chemistry"},{"key":"10.1016\/j.addr.2022.114582_b0550","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/mp400484g","article-title":"Quality by Design Approach for Understanding the Critical Quality Attributes of Cyclosporine Ophthalmic Emulsion","volume":"11","author":"Rahman","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0555","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcis.2015.10.024","article-title":"Structural characteristics of oil-poor dilutable fish oil omega-3 microemulsions for ophthalmic applications","volume":"463","author":"Lidich","year":"2016","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2022.114582_b0560","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.colsurfb.2018.09.063","article-title":"Potentiality of microemulsion systems in treatment of ophthalmic disorders: keratoconus and dry eye syndrome\u2013In vivo study","volume":"173","author":"Lidich","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2022.114582_b0565","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/jop.2018.0031","article-title":"Preclinical Evaluation of a New Hydroxypropyl-Guar Phospholipid Nanoemulsion-Based Artificial Tear Formulation in Models of Corneal Epithelium","volume":"35","author":"Rangarajan","year":"2019","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.addr.2022.114582_b0570","doi-asserted-by":"crossref","first-page":"125101","DOI":"10.1088\/0957-4484\/25\/12\/125101","article-title":"A novel nanoscale-dispersed eye ointment for the treatment of dry eye disease","volume":"25","author":"Zhang","year":"2014","journal-title":"Nanotechnology"},{"key":"10.1016\/j.addr.2022.114582_b0575","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.colsurfb.2016.08.048","article-title":"Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: formulation development, in-vitro and in-vivo studies","volume":"148","author":"Akhter","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2022.114582_b0580","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/jop.2016.0164","article-title":"Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome","volume":"33","author":"Kim","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0585","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2022.114582_b0590","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clae.2012.05.003","article-title":"Effect of three different liposomal eye sprays on ocular comfort and tear film","volume":"35","author":"Pult","year":"2012","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.addr.2022.114582_b0595","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3164\/jcbn.18-27","article-title":"Efficacy of high-affinity liposomal astaxanthin on up-regulation of age-related markers induced by oxidative stress in human corneal epithelial cells","volume":"64","author":"Shimokawa","year":"2019","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.addr.2022.114582_b0600","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1021\/acs.molpharmaceut.8b00516","article-title":"Encapsulation of Azithromycin Ion Pair in Liposome for Enhancing Ocular Delivery and Therapeutic Efficacy on Dry Eye","volume":"15","author":"Ren","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0605","first-page":"3791","article-title":"Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion","volume":"9","author":"Karn","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2022.114582_b0610","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1182\/bloodadvances.2018028431","article-title":"Ocular instillation of vitamin A-coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD","volume":"3","author":"Ohigashi","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.addr.2022.114582_b0615","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.exer.2016.11.010","article-title":"Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: In vitro and ex vivo functionality studies in corneal epithelial cells","volume":"154","author":"Soriano-Roman\u00ed","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0620","doi-asserted-by":"crossref","unstructured":"M. Vicario-de-la-Torre, M. Caballo-Gonz\u00e1lez, E. Vico, L. Morales-Fern\u00e1ndez, P. arriola-Villalobos, B. De Las Heras, J.M. Ben\u00edtez-Del-Castillo, M. Guzm\u00e1n, T. millar, R. herrero-Vanrell, I.T. Molina-Mart\u00ednez, Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film, Polymers (Basel) 10 (2018) 425, https:\/\/doi.org\/10.3390\/polym10040425.","DOI":"10.3390\/polym10040425"},{"issue":"12","key":"10.1016\/j.addr.2022.114582_b0625","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1167\/iovs.14-14700","article-title":"Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film","volume":"55","author":"Vicario-de-la-Torre","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0630","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clae.2017.11.004","article-title":"Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment","volume":"41","author":"Acar","year":"2018","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.addr.2022.114582_b0635","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clae.2009.12.007","article-title":"Effect of a liposomal spray on the pre-ocular tear film","volume":"33","author":"Craig","year":"2010","journal-title":"Cont. Lens Anterior Eye"},{"key":"10.1016\/j.addr.2022.114582_b0640","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1463-5224.2010.00834.x","article-title":"Efficacy of topically applied liposome- bound tetracycline in the treatment of dry eye model","volume":"14","author":"Shafaa","year":"2011","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0645","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1021\/acs.biomac.6b00054","article-title":"Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery","volume":"17","author":"Prosperi-Porta","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2022.114582_b0650","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0655","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijpharm.2013.07.002","article-title":"Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation","volume":"455","author":"Luschmann","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0660","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/acs.molpharmaceut.7b00939","article-title":"Poloxamer 407\/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery","volume":"15","author":"Grimaudo","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0665","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.2147\/IJN.S173691","article-title":"Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles","volume":"13","author":"Shen","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2022.114582_b0670","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1080\/10717544.2018.1458923","article-title":"Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies","volume":"25","author":"Yu","year":"2018","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.addr.2022.114582_b0675","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1167\/iovs.11-8829","article-title":"A Novel Cyclosporin A Aqueous Formulation for Dry Eye Treatment: In Vitro and In Vivo Evaluation","volume":"53","author":"Di Tommaso","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery","volume":"4","author":"Cholkar","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.addr.2022.114582_b0685","first-page":"2921","article-title":"Cyclosporine A micellar delivery system for dry eyes","volume":"11","author":"Kang","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2022.114582_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2015.11.059","article-title":"Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca","volume":"140","author":"Yingfang","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2022.114582_b0695","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.colsurfb.2012.10.055","article-title":"Poloxamine micellar solubilization of \u03b1-tocopherol for topical ocular treatment","volume":"103","author":"Ribeiro","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2022.114582_b0700","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2014.12.017","article-title":"Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal gland","volume":"208","author":"Hsueh","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b0705","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1039\/C9NR00376B","article-title":"Synergistically dual-functional nano eye-drops for simultaneously anti- inflammatory and anti-oxidative treatment of dry eye disease","volume":"11","author":"Li","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2022.114582_b0710","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpharm.2012.08.016","article-title":"Cyclosporin nanosphere formulation for ophthalmic administration","volume":"437","author":"Khan","year":"2012","journal-title":"Int. J. Pharmaceutics"},{"key":"10.1016\/j.addr.2022.114582_b0715","first-page":"32","article-title":"Cytotoxicity and anti-inflammatory activity of cyclosporine a loaded PLGA nanoparticles for ocular use","volume":"69","author":"Hermans","year":"2014","journal-title":"Pharmazie"},{"key":"10.1016\/j.addr.2022.114582_b0720","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3109\/10717544.2016.1172368","article-title":"In vivo tissue distribution and efficacy studies for cyclosporine A loaded nano-decorated subconjunctival implants","volume":"23","author":"Yavuz","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2022.114582_b0725","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","article-title":"Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0730","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.colsurfb.2017.05.064","article-title":"pH triggered controlled drug delivery from contact lenses: addressing the challenges of drug leaching during sterilization and storage","volume":"157","author":"Maulvi","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2022.114582_b0735","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijpharm.2017.07.044","article-title":"Formulations and toxicologic in vivo studies of aqueous cyclosporine A eye drops with cyclodextrin nanoparticles","volume":"529","author":"J\u00f3hannsd\u00f3ttir","year":"2017","journal-title":"Int. J. Pharmaceutics"},{"key":"10.1016\/j.addr.2022.114582_b0740","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2011.01.010","article-title":"Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies","volume":"151","author":"Aksungur","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b0745","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.2147\/IJN.S173198","article-title":"Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief","volume":"13","author":"Huang","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2022.114582_b0750","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/ijms18071558","article-title":"Surface Chemistry Interactions of Cationorm with Films by Human Meibum and Tear Film Compounds","volume":"18","author":"Georgiev","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0755","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2018.12.057","article-title":"The ocular pharmacokinetics and biodistribution of phosphosulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery","volume":"557","author":"Wen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0760","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/gt.2012.56","article-title":"A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model","volume":"20","author":"Contreras-Ruiz","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2022.114582_b0765","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1167\/iovs.16-20843","article-title":"Therapeutic Efficacy of Nanocomplex of Poly (Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model","volume":"58","author":"Lee","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0770","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"hamm-Alvarez, A rapamycinbinding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sj\u00f6gren's syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b0775","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1442-9071.2004.00914.x","article-title":"New vehicle based on a microemulsion for topical ocular administration of dexamethasone","volume":"32","author":"Fialho","year":"2004","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0780","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1350-9462(01)00017-9","article-title":"Microemulsions as ocular drug delivery systems: recent developments and future challenges","volume":"21","author":"Vandamme","year":"2002","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0785","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1167\/iovs.18-24758","article-title":"Modulating Contact Lens Discomfort With Anti-Inflammatory Approaches: A Randomized Controlled Trial","volume":"59","author":"Downie","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0790","unstructured":"B. G\u00fcnther, D. Scherer, A. Pettigrew, Semifluorinated alkane compositions, Novaliq GmbH., Heidelberg, US9,770,508 B2, 2017."},{"key":"10.1016\/j.addr.2022.114582_b0795","unstructured":"H. Warouw, R. Ekantini, T. Widayanti, The Effectiveness of Lipofilm Microemulsion Eye Drops in Dry Eye Syndrome by Enhancing The Tear Film Quality, Jurnal Oftalmologi Indonesia (JOI) 7 (2009) 57i61."},{"key":"10.1016\/j.addr.2022.114582_b0800","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2478\/acph-2019-0054","article-title":"In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery","volume":"69","author":"Dukovski","year":"2019","journal-title":"Acta Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0805","series-title":"Ocular Drug Delivery: Advances, Challenges and Applications","first-page":"53","article-title":"Topical versus systemic ocular drug delivery","author":"Bennett","year":"2016"},{"key":"10.1016\/j.addr.2022.114582_b0810","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-018-2556-5","article-title":"Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (CEQUA\u00ae) for Dry Eye Disease","volume":"36","author":"Mandal","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114582_b0815","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40267-016-0319-0","article-title":"Cationorm\u00ae (cationic emulsion eye drops) in dry eye disease: a guide to its use","volume":"32","author":"Lyseng-Williamson","year":"2016","journal-title":"Drugs Ther. Perspect."},{"key":"10.1016\/j.addr.2022.114582_b0820","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114582_b0825","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40199-018-00235-2","article-title":"Formation of nanosuspensions in bottom-up approach: theories and optimization","volume":"27","author":"Tehrani","year":"2019","journal-title":"Daru"},{"key":"10.1016\/j.addr.2022.114582_b0830","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2013.07.002","article-title":"Developing an in situ nanosuspension: A novel approach towards the efficient administration of poorly soluble drugs at the anterior eye","volume":"50","author":"Luschmann","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0835","first-page":"491","article-title":"Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods","volume":"66","author":"Kim","year":"2011","journal-title":"Pharmazie"},{"key":"10.1016\/j.addr.2022.114582_b0840","first-page":"283","article-title":"Preparation and evaluation of vitamin A nanosuspension as a novel ocular drug delivery","volume":"2","author":"Akhgari","year":"2015","journal-title":"Nanomed. J."},{"key":"10.1016\/j.addr.2022.114582_b0845","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A Comparison of Vitamin A and Cyclosporine A 0.05% Eye Drops for Treatment of Dry Eye Syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b0850","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exer.2016.07.003","article-title":"Size effect of rebamipide ophthalmic nanodispersions on its therapeutic efficacy for corneal wound healing","volume":"151","author":"Nagai","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2022.114582_b0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2003.09.016","article-title":"Vesicular systems in ocular drug delivery: an overview","volume":"269","author":"Kaur","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ICO.0b013e31821b71e6","article-title":"Effectiveness of artificial tears in the management of evaporative dry eye","volume":"31","author":"McCann","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0865","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/nano11010070","article-title":"Recent Advances in Nanomicelles Delivery Systems","volume":"11","author":"Tawfik","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.addr.2022.114582_b0870","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijpharm.2017.09.005","article-title":"Polymeric micelles: Basic research to clinical practice","volume":"532","author":"Deshmukh","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0875","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b0880","first-page":"82","article-title":"Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery, Recent Pat","volume":"2","author":"Cholkar","year":"2012","journal-title":"Nanomed."},{"key":"10.1016\/j.addr.2022.114582_b0885","first-page":"20","article-title":"Excipient update-Soluplus\u00ae: An understanding of supersaturation from amorphous solid dispersions","volume":"15","author":"Tsinman","year":"2015","journal-title":"Drug Development & Delivery"},{"issue":"1","key":"10.1016\/j.addr.2022.114582_b0890","article-title":"Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation","volume":"5","author":"Guo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2022.114582_b0895","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.xphs.2016.03.006","article-title":"\u03b1-Lipoic Acid in Soluplus\u00ae Polymeric Nanomicelles for Ocular Treatment of Diabetes-Associated Corneal Diseases","volume":"105","author":"Alvarez-Rivera","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.addr.2022.114582_b0900","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1167\/iovs.16-19159","article-title":"Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation Ina Murine Model of Sj\u00f6gren\u2019s Syndrome","volume":"58","author":"Shah","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2022.114582_b0905","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2018.0106","article-title":"Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits","volume":"35","author":"Weiss","year":"2019","journal-title":"J. Ocul. pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0910","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/187221108784534081","article-title":"Recent Advances and Patents on Solid Lipid Nanoparticles","volume":"2","author":"Sawant","year":"2008","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.addr.2022.114582_b0915","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2230-973X.167661","article-title":"Nanostructured Lipid Carriers: An Emerging Platform for Improving Oral Bioavailability of Lipophilic Drugs","volume":"5","author":"Khan","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.addr.2022.114582_b0920","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2009.04.021","article-title":"Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery","volume":"137","author":"Shen","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b0925","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.10.008","article-title":"Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution","volume":"402","author":"Shen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0930","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/ICO.0000000000001867","article-title":"Impact of Nanostructured Lipid Carriers as an Artificial Tear Film in a Rabbit Evaporative Dry Eye Model","volume":"38","author":"Niamprem","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2022.114582_b0935","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/chem.201504355","article-title":"A Divalent PAMAM-Based MatrixMmetalloproteinase\/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome","volume":"22","author":"Richichi","year":"2016","journal-title":"Chemistry"},{"key":"10.1016\/j.addr.2022.114582_b0940","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jtos.2018.05.004","article-title":"Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis","volume":"16","author":"Lin","year":"2018","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.addr.2022.114582_b0945","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1139\/cjc-2017-0193","article-title":"Dendrimers for ocular drug delivery","volume":"95","author":"Lancina","year":"2017","journal-title":"Can. J. Chem."},{"key":"10.1016\/j.addr.2022.114582_b0950","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1021\/bm800276d","article-title":"Why is Chitosan Mucoadhesive?","volume":"9","author":"Sogias","year":"2008","journal-title":"Biomacromolecules"},{"issue":"1-2","key":"10.1016\/j.addr.2022.114582_b0955","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0960","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fchem.2017.00103","article-title":"Dual Coating of Liposomes as Encapsulating Matrix of Antimicrobial Peptides: Development and Characterization","volume":"5","author":"Gomaa","year":"2017","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2022.114582_b0965","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/jop.2017.0052","article-title":"Relevance of Lipid-Based Products in the Management of Dry Eye Disease","volume":"33","author":"Garrigue","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0970","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/gt.2012.56","article-title":"A nanomedicine to treat ocular surface inflammation: performance on an experimental dry eye murine model","volume":"20","author":"Contreras-Ruiz","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2022.114582_b0975","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1039\/C9NR00376B","article-title":"Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease","volume":"11","author":"Li","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2022.114582_b0980","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/jop.2009.0074","article-title":"Novel Nanoparticulate Gel Formulations of Steroids for the Treatment of Macular Edema","volume":"26","author":"Boddu","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114582_b0985","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12274-014-0547-3","article-title":"Phenylboronic acid modified mucoadhesive nanoparticle drug carriers facilitate weekly treatment of experimentally induced dry eye syndrome","volume":"8","author":"Liu","year":"2015","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2022.114582_b0990","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2018.12.057","article-title":"The ocular pharmacokinetics and biodistribution of phosphosulindac (OXT-328) formulated in nanoparticles: enhanced and targeted tissue drug delivery","volume":"557","author":"Wen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114582_b0995","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/nn506599f","article-title":"Ocular drug delivery nanowafer with enhanced therapeutic efficacy","volume":"9","author":"Yuan","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2022.114582_b1000","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/17435390.2016.1153165","article-title":"Safety and toxicity of nanomaterials for ocular drug delivery applications","volume":"10","author":"Mehra","year":"2016","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.addr.2022.114582_b1005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2015.07.007","article-title":"Dexamethasone nanowafer as an effective therapy for dry eye disease","volume":"213","author":"Coursey","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2022.114582_b1010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3341\/kjo.2021.0126","article-title":"New Biodegradable Drug Delivery System for Patients with Dry Eye","volume":"35","author":"Park","year":"2021","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b1015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S229405","article-title":"Preliminary In Vivo Safety Evaluation of a Tacrolimus Eye Drop Formulation Using Hydroxypropyl Beta Cyclodextrin After Ocular Administration in NZW Rabbits","volume":"14","author":"Mahmoudi","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2022.114582_b1020","doi-asserted-by":"crossref","unstructured":"P.K. Gupta, N. Venkateswaran, The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares, Ther. Adv. Ophthalmol. 13, (2021) 25158414211012797, https:\/\/doi.org\/10.1177\/25158414211012797.","DOI":"10.1177\/25158414211012797"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22004720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22004720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:31:28Z","timestamp":1759210288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22004720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":204,"alternative-id":["S0169409X22004720"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114582","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel drug delivery systems for the management of dry eye","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114582"}}